Identification of Pbx1, a Potential Oncogene, as a Notch3 Target Gene in Ovarian Cancer

Joon T. Park,1,3 Ie-Ming Shih,1,2,3 and Tian-Li Wang2

1Department of Pathology, 2Departments of Oncology, Gynecology and Obstetrics, and 3Pathobiology Graduate Program, Johns Hopkins Medical Institutions, Baltimore, Maryland

Abstract

Notch3 gene amplification has recently been identified in ovarian cancer but the Notch3 effectors that are involved in the development of ovarian cancer remain elusive. In this study, we have identified Pbx1, a proto-oncogene in hematopoeitic malignancy, as a Notch3 target gene. Pbx1 expression is transcriptionally regulated by Notch3 activation, and Notch3/CSL protein complex directly binds to the Pbx1 promoter segment harboring the CSL-binding sequence. The growth-inhibitory effect of γ-secretase inhibitor could be partially reversed by ectopic Pbx1 expression. Furthermore, functional studies by Pbx1 short hairpin RNA knockdown show that Pbx1 is essential for cell proliferation and tumorigenicity. Taken together, the above findings indicate that Pbx1 is a direct Notch3-regulated gene that mediates the survival signal of Notch3 in ovarian cancer. [Cancer Res 2008;68(21):8852–60]

Introduction

Cancer development has been known to share many molecular frameworks with embryonic development, tissue renewal, and differentiation (1). For example, in normal tissues, the Notch signaling pathway is activated under strict temporal and spatial control during tissue regeneration and cell fate determination. In contrast, during tumor development, Notch is constitutively activated and its sustained activation could be a result of genetic or epigenetic alterations. In human cancer, activation of the Notch receptor due to point mutations and gene translocations has been found in T-cell leukemia/lymphoma, non–small cell lung cancer, and breast carcinoma (2–5). Based on a genome-wide analysis of DNA copy number changes using both digital karyotyping (6) and single nucleotide polymorphism array analysis (7), we have identified Notch3 gene amplification in high-grade ovarian serous carcinomas (8). Notch3 gene amplification correlated with DNA copy number changes using both digital karyotyping (6) and single nucleotide polymorphism array analysis (7), we have identified Notch3 gene amplification in high-grade ovarian serous carcinomas (8). Notch3 gene amplification correlated with expression and pathway activation in ovarian serous carcinoma tissues. Functional inactivation of Notch3 either by γ-secretase inhibitor (GSI) or by Notch3-specific small interfering RNA (siRNA) resulted in suppression of cell proliferation and induction of apoptosis, suggesting that Notch3 activation is an important survival signal in ovarian cancer cells.

The Notch signaling pathway is evolutionarily conserved. The primary members of this signaling pathway include Notch ligands (Delta and Jagged), Notch receptors (Notch1, Notch2, Notch3, and Notch4), the nuclear transcription factors such as CSL (also known as RBP-J and CBF1) that bind to Notch intracellular fragment, and the target genes that are controlled by Notch3/CSL coactivator. Activation of Notch signaling is initiated by receptor-ligand interaction, which leads to proteolytic cleavages that liberate the Notch intracellular cytoplasmic domain (NICD) from the plasma membrane. NICD translocates to the nucleus and binds to transcription complexes that contain CSL. NICD binding converts the CSL complex from a transcription repressor to a transcription activator, thereby initiating transcription of downstream effectors. The diverse biological activities of Notch signaling are thought to be mediated by the context-dependent expression of a heterogeneous group of downstream effectors.

Although several downstream genes in the Notch pathway have been reported (9–12), it is not known which of them are regulated by Notch3 in ovarian cancer cells. We have analyzed the known Notch target genes represented in the serial analysis of gene expression database in ovarian tissues. We found that the expression level of most of the known target genes, such as the Hes gene family, was extremely low and did not correlate with the expression level of Notch3 in ovarian cancer tissues. This suggested that the Notch3 targets in ovarian cancer were distinct from other known Notch targets. To identify candidate Notch3 targets, we analyzed the genes that were down-regulated following functional inactivation of Notch3 by treatment of ovarian cancer cells with GSI in this study. We selected one of the most promising candidate genes, Pbx1, for further characterization.

Materials and Methods

Affymetrix GeneChip analysis. Cancer cell lines, including OVCAR3, A2780, and MCF7, were cultured in the presence of 1 μmol/L GSI (EMD Chemicals) for 48 h. Control cells were cultured in the presence of DMSO under the same experimental condition. Total RNA was purified using a RNA purification kit (Qiagen) and RNA samples were hybridized onto the GeneChip arrays, HG-U133 Plus 2.0 (Affymetrix), which were spotted with over 47,000 human transcripts. The dChip software package4 was used for data analysis. By comparing global gene expression profiles between GSI-treated and mock-treated cells, we selected the differentially expressed genes with levels >2-fold in all three tested cell lines. The differentially expressed genes were presented as individual boxes with pseudocolor to indicate gene expression levels.

Quantitative real-time PCR. Relative transcript expression levels were measured by quantitative real-time PCR using method previously described (13). The primer sequences were shown in Supplementary Table S1. PCRs were performed in triplicates using an iCycler (Bio-Rad). The amplified products were quantified by fluorescence intensity of SYBR Green I (Molecular Probes). Average fold changes were calculated by differences in threshold cycles (Ct) between pairs of samples to be compared.

Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).

Requests for reprints: Tian-Li Wang, Johns Hopkins Medical Institutions, Cancer Research Building II, Room 306, 1550 Orleans Street, Baltimore, MD 21231. Phone: 410-502-0863; Fax: 410-502-7943; E-mail: tlw@jhmi.edu.

DOI: 10.1158/0008-5472.CAN-08-0517

4 http://biosun1.harvard.edu/complab/dchip/
A precursor gene was used for normalizing the cDNA concentration of each sample.

**Western blot analysis.** Protein lysates were prepared by resuspending cell pellets in Laemmli sample buffer containing 5% β-mercaptoethanol. Protein lysates were separated by 4% to 12% Tris-glycine gel electrophoresis and transferred onto polyvinylidene difluoride membrane using semidy membranes apparatus (Bio-Rad). The membrane was blocked with 5% nonfat dry milk in TBST (20 mmol/L Tris-HCl, 0.5 mol/L NaCl, 0.1% Tween 20) and incubated with primary antibody at room temperature for 3 h followed by washing with TBST. Subsequently, the membrane was incubated with horseradish peroxidase (HRP)-conjugated secondary antibody and detected with enhanced chemiluminescence solution (Thermo Scientific). Antibodies used in this study include anti-NICD3 (Santa Cruz Biotechnology), anti-NH₂-terminal extracellular subunit of Notch3 (Abnova), anti-Pbx1 (Santa Cruz Biotechnology), and anti-Pbx1b (gift from Dr. Michael Cleary, Stanford University, Stanford, CA).

**Chromatin immunoprecipitation assay.** Chromatin immunoprecipitation (ChIP) was performed using the ChIP-IT enzymatic kit (Active Motif). HEK293 cells were infected with control pBabe-puro retrovirus and pBabe-CSL/V5 retrovirus for 24 h before fixation with 1% paraformaldehyde. The lysates of fixed cells were treated with an enzymatic shearing cocktail (Active Motif), and the soluble fraction was incubated with 4 μL of anti-V5 antibody or normal mouse IgG and precipitated with protein G magnetic beads at 4°C for overnight. The cross-links of the DNA eluate were reversed by heating at 65°C for 6 h, and the samples were treated with protease K (10 μg/mL) at 37°C for 1 h. Quantitative PCR was performed using SYBR Green I–based detection system as described above with the PCR primers that amplified different Pbx1 promoter regions (primer sequences shown in Supplementary Table S1). The input DNA was defined as an aliquot of sheared chromatin before immunoprecipitation and was used to normalize the amount of chromatin used in each experiment as previously described (14).

**Figure 1.** Identification of Pbx1 as a putative Notch3 target gene. A, top, Western blot was performed to assess Notch3 protein expression in a panel of cancer cell lines. OVCAR3, A2780, and MCF7, which express abundant Notch3 proteins, were selected for microarray analysis. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) protein expression was used as loading control. Of note, the three cell lines with Notch3 overexpression also show Pbx1 overexpression. Bottom, Affymetrix GeneChip analysis was performed to identify genes differentially expressed between GSI-treated (1 μmol/L) versus DMSO-treated cancer cells. dChip software was used to analyze the data. A cutoff ratio of 2 was used to select the GSI-sensitive genes. Columns represent experimental samples (cell lines), whereas rows represent genes. The expression level of each gene in an individual specimen is shown as a pseudocolor gradient based on the relative expression level normalized for each gene, where red indicates high expression and green indicates low expression. B, quantitative real-time PCR was performed to confirm the candidate GSI-sensitive genes identified by GeneChip analysis. The genes that can be confirmed by quantitative PCR include Pbx1, glypican-6, histone 4C, histone 4K, and histone 4J. C, Western blot analysis shows that Pbx1 protein is down-regulated by either GSI or Notch3 siRNA. In contrast, mock (no transfection) and scramble siRNA do not have significant effects on Pbx1 protein expression. Cells were incubated with GSI or Notch siRNA for 48 h before assay. D, Western blot analysis of Pbx1 expression in a panel of ovarian tissues. LG, low-grade ovarian serous carcinoma; HG, high-grade ovarian serous carcinoma. *, samples with protein degradation. Pbx1a was found to be more susceptible to protein degradation.
Electrophoretic mobility shift assays. Nuclear extracts were prepared using the NE-PER nuclear and cytoplasmic extraction reagents (Pierce Biotechnology). Electrophoretic mobility shift assay (EMSA) was performed using the LightShift Chemiluminescent EMSA kit (Pierce Biotechnology) according to the manufacturer’s protocol. DNA fragments for two Pbx1 promoter regions (−254 to −111 bp and −354 to −254 bp) were PCR amplified using biotinylated PCR primers. The biotin-labeled DNA fragments were incubated with nuclear lysate from 293 cell transfected with SG5-flag-CSL and/or infected with NICD3 retrovirus. Nuclear protein (5 μg) was incubated with 20 fmol of biotin-labeled DNA probe for 20 min at room temperature. DNA probe/protein complexes were separated by electrophoresis, transferred to a nylon membrane, incubated with streptavidin-HRP, and visualized by chemiluminescence.

Immunohistochemistry. A rabbit polyclonal anti-NICD3 antibody and a mouse anti-Pbx1b primary antibody against Pbx1b (15) were used in immunohistochemistry. Tissue microarrays containing 81 high-grade ovarian serous carcinoma tissues per slide were deparaffinized and antigen retrieved in a citrate buffer (pH 6.0) for 10 min. Immunostaining was performed using an EnVision+ System Peroxidase kit (DAKO). Immunoreactivity. For discordant cases, a third investigator scored and the final intensity score was determined by the majority votes.

Production of Pbx1 and CSL retroviruses and rescue assay. The PCR products of Pbx1a, Pbx1b, and CSL were cloned into an expression vector, pcDNA6 with a V5 tag. The coding sequence of Pbx1a-V5, Pbx1b-V5, and CSL-V5 was subcloned into the pBabe-puro retroviral vector and high-titer retroviral stocks were generated using Phoenix ecotropic packaging cell line. Retroviral gene transfer was performed as previously described (16). For rescue assay, cells were infected with Pbx1a retrovirus and the empty pBabe-puro vector. Cells were cultured in the presence of 0.7, 1.0, 1.5, and 2.0 μmol/L of GSI for 24 h. Mock-treated cells were cultured in the presence of DMSO vehicle control. Average cell counts and SDs were derived from five replicates. Student’s t test was used to determine nuclear immunoreactivity. For discordant cases, a third investigator scored and the final intensity score was determined by the majority votes.

Luciferase reporter assay. Immortalized ovarian surface epithelial (OSE) cells (OSE10) were transfected with pGL3 plasmid (Promega) or pGL3-Pbx1, which contains 3.0-kb Pbx1 promoter (gift from Dr. S. Higashiyama, Ehime University, Ehime, Japan; ref. 17). pRL-Renilla reporter plasmid (Promega), which serves to monitor the transfection efficiency, was cotransfected with the pGL3 plasmid. Transfection was carried out by Lipofectamine 2000 (Invitrogen) and luciferase expression was determined by Dual-Glo luciferase reagent (Promega). The firefly luciferase activity was normalized to luminescence from Renilla luciferase, and the ratio of luminescence from the experimental reporter to luminescence from the control reporter was calculated.

Transfection and cell growth assay. The sequences of Notch3-specific siRNAs and transfection method have been previously described (8). Pbx1 short hairpin RNA (shRNA) plasmid that targeted Pbx1 coding sequence 5′-GCAAGCGACAGAAATCCTGAA-3′ was purchased from the Mission shRNA collection at Sigma-Aldrich. The shRNA sequence was subcloned into a pLKO.1-puro vector. For cell proliferation assays, cells were seeded in 24-well culture plate and transfected with 1 μg Pbx1 shRNA plasmid using Lipofectamine 2000. One day after transfection, cells were plated into 96-well plates at a density of 3,000 per well and cell number was measured at different time points by the incorporation of SYBR Green I using a fluorescence microplate reader (FLUOstar, BMG). To determine if Pbx1 expression is essential for tumor cell survival or vivo, we transfected A2780 ovarian cancer cells with Pbx1 shRNA. Two millions of transfected cells were injected into the s.c. tissue of nude mice. Tumor volume was measured every other day for 18 d.

Results

Identification and validation of Notch3-regulated genes in cancer cells. To elucidate the mechanisms by which Notch3 signaling promotes tumor growth and survival, we first sought to identify Notch3-regulated genes by comparing gene expression between cancer cells treated either with GSI or with DMSO vehicle control. The release of NICD, which is required for Notch signaling, is mediated by γ-secretase. GSI has been shown to potently inhibit γ-secretase, thereby inactivating Notch signaling (18, 19). Ovarian cancer cell lines, including OVCAR3 and A2780, and a breast cancer cell line, MCF7, overexpressing Notch3 were selected for Affymetrix GeneChip analysis (Fig. 1A, top). Genes that showed 2-fold differential expression from all three cell lines were identified using the dChip software (Fig. 1A, bottom). We specifically focused on genes that were suppressed by GSI because those genes were potentially up-regulated by Notch3. Among those genes were Pbx1, glypican-6, histone 1 H4C, 4K, and 4j, and H2A member V and a gene.
containing the RERE repeats. Using quantitative real-time PCR, we were able to confirm five of them (Fig. 1B). Pbx1 (pre-B-cell leukemia transcription factor 1) was selected for further characterization for several reasons. First, by GeneChip analysis, Pbx1 showed the most dramatic and consistent down-regulation by GSI in all three cell lines tested. Second, Pbx1 protein expression correlated with Notch3 expression in cell lines based on Western blot analysis (Fig. 1A, top). Third, Pbx1 fusion protein, E2A-Pbx1, is known as a proto-oncogene in leukemia (20, 21). Lastly, the Pbx1 promoter contained a consensus sequence for CSL/NICD binding.

Two alternatively spliced variants of Pbx1, Pbx1a and Pbx1b, have been previously reported and both share the same sequences, except an additional exon in Pbx1a. Pbx1a encodes 430 amino acids, whereas Pbx1b encodes 347 amino acids. Pbx1b shares the same amino acid sequences as Pbx1a from 1 to 333 amino acids but differs in its last 14 amino acids. Using Western blot and reverse transcription-PCR (RT-PCR) analyses, we found that both splicing variants were present in ovarian cancers, with Pbx1a appearing as the predominant form (Fig. 1A; Supplementary Fig. S1).

The results of GeneChip analysis (based on 2-fold differential expression) did not identify the Notch downstream target genes previously reported in other organ systems. However, when the selection criteria were relaxed, we found that several of the known Notch target genes were moderately down-regulated by GSI (Supplementary Fig. S2A). Quantitative real-time PCR was performed on eight of the previously known target genes, including HeyL, Hey2, TLE2, TLE4, and c-Myc, in the same three cell lines selected for GeneChip analysis. The real-time PCR results showed that a consistent down-regulation of gene expression on GSI treatment could be observed in TLE2 and TLE4 (Supplementary Fig. S2B). In addition, c-Myc and cyclin A2 were significantly decreased by GSI in two of the three cell lines. These results suggested that these four genes may also have a role in mediating the function of Notch3 in some ovarian cancer cells.

**Notch3-dependent Pbx1 expression.** To determine whether Pbx1 expression is associated with Notch3 expression, we used the following approaches. First, we inhibited NICD3 expression using GSI and Notch3-specific siRNA in the Notch3-expressing cell lines OVCAR3, A2780, and MCF7. As shown in Fig. 1C, both Notch3 and Pbx1 protein levels (both splicing isoforms) were significantly reduced by either GSI or Notch3 siRNA treatment. We found that GSI inhibited the expression of NICD3 in a time-dependent fashion (Supplementary Fig. S3A). Similar findings were previously reported (22–24).

To determine whether Pbx1 protein expression correlates with Notch3 protein expression in ovarian cancer tissues, Western blot was performed in a panel of protein lysates prepared from immortalized OSEs, low-grade serous carcinoma tumor tissues, and high-grade serous carcinoma tumor tissues. The result showed that OSEs and low-grade tumors expressed low abundance of Pbx1

![Figure 3](https://example.com)
or Notch3. In comparison, most high-grade tumors expressed high levels of Notch3 and Pbx1 (Fig. 1D).

To determine if protein synthesis was required for suppression of Pbx1 transcription by GSI, cycloheximide was added to the cell culture system to block protein synthesis. Cells overexpressing Notch3 were treated with 1 μmol/L GSI for 6 hours to down-regulate Pbx1 expression. Cells were then washed and incubated with medium with (mock washout) or without GSI. As shown in Supplementary Fig. S4, in the absence of GSI, a rapid up-regulation of Pbx1 transcripts was detected even in the presence of cycloheximide. In contrast, continuous presence of GSI suppressed the Pbx1 transcription. These results indicated that Pbx1 transcription regulation by Notch3 did not require de novo protein synthesis.

Next, we asked if Notch3 was directly involved in transcriptional regulation of Pbx1. Using a Pbx1 promoter-luciferase reporter construct (17), we measured Pbx1 promoter activity in OSE cells derived from normal OSE. This promoter construct, pGL3-Pbx1, includes a 3.0-kb Pbx1 promoter region containing one CSL consensus binding site located at −304 to −292 bp upstream of the translation initiation codon (Fig. 2A, left). pGL3-Pbx1 was transfected into OSE cells, which were previously engineered to express CSL, NICD3, or both. As shown in Fig. 2A (right), luciferase activity was significantly higher in pGL3-Pbx1-transfected groups compared with pGL3-transfected groups. A low level of luciferase activity was detected in pGL3-Pbx1-transfected cells even in the absence of CSL or NICD3 virus transduction, likely due to endogenous CSL and NICD3 in OSE cells. Luciferase activity was further enhanced in cells cotransduced with CSL and NICD3. To test the specificity of the promoter activity, we created a promoter construct that carried mutated CSL-binding site (GTATAACT). When assayed in OSE cells, luciferase activity driven by the pGL3-Pbx1 mutant reporter was significantly reduced under all experimental conditions, indicating that a functional CSL site was required for promoter activity.

Pbx1 promoter reporter construct was also used to test promoter activity in cell lines (OVCAR3, A2780, and MCF7) that expressed both Notch3 and Pbx1. In these experiments, we determined if inactivating Notch3 using GSI or Notch3 siRNA would lead to inhibition of luciferase reporter activity. Indeed, in all Notch3-expressing cell lines examined, GSI and Notch3 siRNA treatment led to a significant suppression in Pbx1 promoter reporter activity (Fig. 2B).

Correlation of Pbx1b expression and NICD3 immunoreactivity in tumor samples. The above results showed that Pbx1 expression was transcriptionally regulated by Notch3 pathway

Figure 4. ChIP and EMSA of Pbx1 promoter region. A, ChIP assay was performed to determine the CSL-binding region at the Pbx1 promoter. Real-time PCR was performed on fragmented chromatin precipitated by an anti-V5 antibody (Ab) from 293T cells previously infected with CSL-V5 virus or control virus. PCR primers were designed to amplify four different regions at the Pbx1 promoter (−254/−111 bp, −354/−254 bp, −1,074/−960 bp, and −1,252/−1,127 bp). Results were normalized to the total input of chromatin DNA and were presented as the fold change of CSL-V5–infected cells relative to control virus–infected cells. Columns, mean of triplicate experiments; bars, SD. B, EMSA was performed on two adjacent regions at the Pbx1 promoter, −254/−111 bp and −354/−254 bp. The −354/−254 bp region contains the CSL consensus binding sequence. Biotin-labeled DNA probe for each promoter region was incubated with nuclear lysates from HEK293 cells transfected with CSL and/or transduced with NICD3 virus. The specificity of CSL binding was determined in a competition reaction in which a 100-fold molar excess of unlabeled DNA probe was added to the binding reaction. The binding complex was resolved by electrophoresis on a 4% to 12% Tris-borate EDTA gel. The position of biotin-labeled probe was detected with avidin-HRP followed by chemiluminescence.
activation. To determine if this association also occurred in vivo, we performed immunohistochemistry to assess Notch3 and Pbx1 expression levels in a series of ovarian serous carcinoma tissues. After an extensive search for Pbx1 antibodies that worked in formalin-fixed, paraffin-embedded tissues, we only identified an antibody against the COOH terminus of Pbx1b that recognized the antigen in paraffin sections. The specificity of this antibody was confirmed by showing that a single protein band, corresponding to the molecular mass of Pbx1b protein, was detected in Pbx1b gene-transduced MPSC1 cells but not in vector-transduced or in parental MPSC1 cells (Fig. 3A). Because Western blot and RT-PCR both showed coexpression of Pbx1a and Pbx1b in ovarian tissues, Pbx1b immunoreactivity was used as the surrogate marker for Pbx1 expression. The specificity of the Notch3 antibody and its application in immunohistochemistry has been shown in previous reports (8, 16). Because nuclear localization of Notch is an indication of pathway activation and Pbx1b is a nuclear transcription factor, we focused on evaluating nuclear immunoreactivity of both proteins. Pbx1b nuclear immunoreactivity was always either intense or very weak/undetectable, whereas Notch3 nuclear immunoreactivity showed a range of intensity (0, 1+, 2+, and 3+). Representative immunostaining results on tissue sections are shown in Fig. 3B. Using the Cochran-Armitage trend test, we found that there was a significant trend between Pbx1b and Notch3 nuclear co-overexpression in ovarian serous carcinoma tissues (P < 0.0001; Fig. 3B).

To further determine the Pbx1 expression pattern in OSE, low-grade, and high-grade serous carcinoma tissues, we performed quantitative RT-PCR using PCR primers that amplified both Pbx1a and Pbx1b. The data showed significantly higher Pbx1 mRNA levels in high-grade serous carcinoma tissues than in normal OSE cells or high-grade serous carcinomas (Supplementary Fig. S5), a finding consistent with previous reports (8, 16). Because nuclear localization of Notch is an indication of pathway activation and Pbx1b is a nuclear transcription factor, we focused on evaluating nuclear immunoreactivity of both proteins. Pbx1b nuclear immunoreactivity was always either intense or very weak/undetectable, whereas Notch3 nuclear immunoreactivity showed a range of intensity (0, 1+, 2+, and 3+). Representative immunostaining results on tissue sections are shown in Fig. 3B. Using the Cochran-Armitage trend test, we found that there was a significant trend between Pbx1b and Notch3 nuclear co-overexpression in ovarian serous carcinoma tissues (P < 0.0001; Fig. 3B).

Direct interaction between CSL/NICD3 protein complex and the Pbx1 promoter region. The above findings indicated transcriptional regulation of Pbx1 by Notch3 and were suggestive of direct interaction of Notch3/CSL complex with the Pbx1 promoter. To determine if this is the case, we performed ChIP and EMSA. ChIP using an anti-V5 tag antibody in CSL-V5–transduced HEK293 cells compared with vector-transduced HEK293 cells showed that among different Pbx1 promoter segments, a fragment spanning nucleotides −354 to −254 bp (−354/−254) containing the canonical consensus CSL-binding sequence bound most robustly to the CSL protein (Fig. 4A). Immunoprecipitation of the CSL-containing DNA segment seemed to be specific, as ChIP using control mouse IgG instead of anti-V5 antibody did not bring down this fragment (data not shown).

EMSA was performed to determine if the NICD3/CSL protein complex directly bound to the Pbx1 promoter region containing the CSL-binding sequence. For this purpose, a DNA probe spanning the −354/−254 region at the Pbx1 promoter containing the canonical CSL consensus site was generated. An adjacent DNA segment (−254/−111) was used as a control. As shown in Fig. 4B, a band shift can be detected in the CSL-expressing group only when the −354/−254 probe was used in the assay. Binding of the CSL complex to the labeled probe could be competitively inhibited by 100-fold molar excess of unlabeled probes (Fig. 4B). Furthermore, when NICD3 was coexpressed with CSL in the same cells, the band shifted to a higher molecular weight, corresponding to the NICD3/CSL complex. This higher molecular weight band is more intense than the band formed in the absence of Notch3, suggesting that the NICD3/CSL complex forms a more stable complex with the Pbx1 promoter. A similar effect in the molecular weight shift has been reported in the Notch1/CSL complex (9).

Functional roles of Pbx1 in Notch3 signaling. To determine the biological effects of Pbx1 in mediating Notch3 signaling, we examined if ectopic expression of Pbx1 (Fig. 5A) could reverse GSI-mediated growth inhibition in A2780, OVCAR3, and MCF7 cells. We found that compared with control virus expression, constitutive expression of ectopic Pbx1 could significantly protect the cells from the growth-inhibitory effect of GSI at 1 to 2 μmol/L concentration (Fig. 5B). However, ectopic expression of Pbx1 did not increase cell number in the same cell lines (data not shown), suggesting that Pbx1 alone is not sufficient to promote cell growth.

To assess if Pbx1 was essential for ovarian cancer cell growth, we examined the effect of Pbx1 shRNA on cell proliferation. Pbx1 shRNA was transduced into A2780, OVCAR3, and MCF7 cells, all of which expressed both Notch3 and Pbx1. The efficiency of Pbx1
shRNA in suppressing Pbx1 protein expression was shown by Western blot analysis (Fig. 6A). Among all three cell lines, compared with cells with mock transfection or control shRNA transfection, Pbx1 shRNA–transfected cells showed a significant reduction in cell number (Fig. 6B). The decrease in cell number in Pbx1 shRNA–treated cells was due to suppression of DNA synthesis as evidenced by reduced bromodeoxyuridine (BrdUrd) uptake (Fig. 6C). Increased apoptosis did not seem to be a factor because the percentage of apoptotic cells was similar between Pbx1 shRNA–treated and control shRNA–treated cells (data not shown).

In ovarian cancer cells, including MPSC1, SKOV3, and TOV21G, which did not express detectable levels of Pbx1 or Notch3, Pbx1 shRNA did not have significant effects on cell growth (Fig. 6B).

To determine the role of Pbx1 on tumor development, we used shRNA to knock down Pbx1 expression in A2780 cells and measured their ability to form s.c. tumors in athymic nu/nu mice. We observed a difference in forming s.c. tumors between Pbx1 shRNA–treated and control shRNA–treated cells (data not shown). In ovarian cancer cells, including MPSC1, SKOV3, and TOV21G, which did not express detectable levels of Pbx1 or Notch3, Pbx1 shRNA did not have significant effects on cell growth (Fig. 6B).

We observed a difference in forming s.c. tumors between Pbx1 shRNA–treated versus control shRNA–treated groups (Fig. 6D). Eight of 10 mice in the control shRNA–treated group grew tumors, whereas only 2 of 10 mice in the Pbx1 shRNA–treated group grew tumor (P < 0.005, Fisher’s exact test). The two tumors that grew in the Pbx1 shRNA–transfected group were examined for Pbx1 expression by immunohistochemistry and quantitative RT-PCR and were found to harbor significant Pbx1 expression. This result suggests that tumor cell formation in these animals was likely the result of clonal selection in favor of Pbx1-expressing cells. However, there is no significant difference in tumor volume between Pbx1 shRNA–treated versus control shRNA–treated group possibly due to high variance of tumor size.

Discussion
Notch signaling is involved in diverse cellular functions, including cell fate determination, morphogenesis, and oncogenesis, which are mediated by unique Notch downstream effectors. Expression of specific Notch downstream genes is tissue and context dependent. Although a repertoire of Notch-controlled genes has been identified, the Notch effectors that are involved in the development of human cancer remain elusive. In this study, we report a novel Notch3-regulated gene, Pbx1, in ovarian cancer cells and show that transcriptional regulation of Pbx1 is a direct consequence of Notch3 activation. Our functional studies provide evidence that Pbx1 mediates, at least in part, the effect of Notch activation in the development of ovarian cancer.

Several approaches were used in this study to show that Pbx1 was the direct downstream target gene of the Notch3 signaling
pathway. First, Pbx1 promoter activity increased on ectopic expression of CSL and NICD3 and decreased after treating cells with either GSI or Notch3-specific siRNA. Furthermore, mutating CSL consensus binding site at Pbx1 promoter leads to an abolishment of Pbx1 promoter activity. Therefore, our data showed a significant association between Notch3 pathway activation and Pbx1 transcription activity. Second, ChIP and gel shift assays showed that there was a direct interaction between the NICD3/CSL complex and the Pbx1 promoter sequence containing the consensus CSL-binding site. Third, constitutive expression of Pbx1 could rescue cells, at least partially, from the growth-suppressive effects of GSI. Furthermore, our recent study using a coculture system also showed that Pbx1 promoter activity was stimulated on Notch3 and Jagged-1 binding, and this activity was attenuated by Notch3 siRNA (25).

In this study, GSI treatment in Notch3-expressing cell lines was associated with a time-dependent decrease of NICD3 protein. This observation is similar to those previously reported (22–24). Furthermore, we also found that the expression of full-length Notch3 as well as NH2-terminal extracellular subunit of Notch3 was also down-regulated by GSI (Supplementary Fig. S3B). This could be due to Notch3 transcription, which is regulated by NICD3 through a positive feedback loop. Accordingly, when NICD3 generation was inhibited by GSI, it also affected the transcription of Notch3, leading to further reduction of the Notch3 protein expression. Indeed, several studies have shown the positive feedback regulation of Notch expression by its own signaling in a variety of organisms, including Caenorhabditis elegans (26), Drosophila (27), and mouse (28). Although the above is our preferred explanation, it remains possible that GSI can directly affect transcription of certain genes in addition to its effect in inhibiting γ-secretase.

In this study, Pbx1 shRNA was found to inhibit proliferation but did not have a significant effect on apoptosis. Our earlier study, however, showed that inhibiting Notch3 signaling affected both proliferation and apoptosis (8). These results suggest that Pbx1 mediates part, but not all, of the effects of the Notch3 pathway activation. Toward this end, we have identified other candidate Notch3-regulated genes in ovarian carcinoma through microarray analysis. Although confirmation is required, it is possible that some of these genes work in concert with Pbx1 to mediate the tumor survival of Notch3 activation.

Pbx1 is a member of the three–amino acid loop extension class of homeodomain transcription factors and can form multimeric transcriptional complexes with other homeodomain proteins, such as Hox (29) and MyoD (30), and can participate in a variety of transcriptional regulatory processes. Deletion of Pbx1 resulted in organ hypoplasia and defects in B-cell differentiation, indicating that Pbx1 expression is essential for organ development (31–35). Pbx1 was initially identified as a proto-oncogene in human leukemia cells harboring the translocation t(1;19)(q23;p13.3) that produced an oncogenic E2A-Pbx1 fusion protein (20, 36). The fusion of the potent transcriptional activation domain of E2A in chromosome 19 onto the DNA-binding domain of Pbx1 in chromosome 1 contributes to the acute lymphoblastic phenotype by modifying expression of genes normally responsive to Pbx1. In addition to leukemia, Pbx1 is highly expressed in melanoma cells and Pbx1 gene knockdown leads to growth suppression in melanoma cells (17). Consistent with this result, we showed in this report that knockdown of Pbx1 significantly reduced cellular proliferation and tumorigenicity in cancer cells over-expressing both Pbx1 and Notch3, suggesting that Pbx1 expression provides a survival signal in cancer cells that are dependent on Pbx1 pathway.

Identification of Pbx1 as a Notch3-regulated gene in cancer cells has the following biological and clinical implications. First, our results further support the view that Notch3 signaling is mediated by different downstream targets in different pathophysiologic settings. In ovarian cancer, Pbx1 seems to be one of the downstream targets that mediate Notch3 function. Second, Pbx1 may function as a molecular hub for different pathways, including Notch and Hox. It has been shown that Pbx1 can directly interact with Hox (37) and other homeodomain proteins, including Meis (38). The Pbx1-Meis complex functions as a cofactor with Hox to further enhance DNA-binding activity (15). The critical role of Hox has been well documented in a variety of human neoplastic diseases, including leukemia (39, 40) and ovarian cancer (41–43).

Our findings suggest that Notch3 activation potentially modulates the function of Hox protein through transcriptional up-regulation of Pbx1. Further experiments are needed to more fully establish the putative link between Notch3 and Hox in the tumorigenesis of ovarian cancer. Third, the findings that Pbx1 is essential for ovarian cancer cell survival and proliferation suggest that Pbx1 might be a potential target for therapeutics in ovarian cancer in which Notch3 is activated. These tumors may have developed Notch3-Pbx1 pathway-dependent cellular machinery for growth and survival. If so, withdrawal or inhibition of Pbx1 expression may have a potent growth-inhibitory effect. The cytotoxicity associated with GSI, especially on the gastrointestinal tract, is a major obstacle of its application to cancer patients (19, 44). Alternative strategies to specifically block Notch downstream targets, such as Pbx1, are warrant to be developed.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Acknowledgments

Received 2/11/2008; revised 7/2/2008; accepted 8/6/2008.

Grant support: American Cancer Society Research Scholar Grant (T-L. Wang), Ovarian Cancer Research Foundation Individual Investigator Grant (T-L. Wang), Department of Defense New Investigator Research Grant W81XWH (T-L. Wang), NIH career development award P50CA098525 (T-L. Wang), American Cancer Society Institutional Research Grant (T-L. Wang), and NIH grants CA129080 and CA103937 (I-M. Shih).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

We thank Dr. Michael Cleary for the anti-Pbx1 antibody, Dr. S. Higashiyama for the pGL3-Pbx1 promoter construct, Dr. Diane Hayward (Johns Hopkins University) for the S5G5-flag-CSL plasmid, and Drs. Ching-Hung Lin and Kuan-Ting Kuo for help in statistical analyses.

References


Identification of *Pbx1*, a Potential Oncogene, as a Notch3 Target Gene in Ovarian Cancer

Joon T. Park, Ie-Ming Shih and Tian-Li Wang


**Updated version**
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/68/21/8852

**Supplementary Material**
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2008/10/23/68.21.8852.DC1

**Cited articles**
This article cites 44 articles, 23 of which you can access for free at:
http://cancerres.aacrjournals.org/content/68/21/8852.full#ref-list-1

**Citing articles**
This article has been cited by 9 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/68/21/8852.full#related-urls

**E-mail alerts**
Sign up to receive free email-alerts related to this article or journal.

**Reprints and Subscriptions**
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

**Permissions**
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.